Clinical Trial Update: A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the combination of IDH1 inhibitor ivosidenib or IDH2 inhibitor enasidenib with induction and consolidation therapy followed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts-2

Drugs mentioned

• Enasidenib (Idhifa) (enasidenib)
• Ivosidenib (Tibsovo) (ivosidenib)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 3 | Status: ACTIVE_NOT_RECRUITING